Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
NeuGATE Theranostics
Country
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
NG101m Adjuvant Therapy in Glioblastoma Patients
Phase 1
Not yet recruiting
Conditions
Glioblastoma Multiforme
Interventions
Radiation: Intensity-modulated radiation therapy
Drug: Temozolomide
Drug: NG101m
Subscribe
First Posted Date
2020-05-04
Last Posted Date
2023-04-18
Lead Sponsor
NeuGATE Theranostics
Target Recruit Count
52
Registration Number
NCT04373785
Locations
🇺🇸
Yvonne Kew MD, PLLC, Houston, Texas, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy